Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H32N4O3S |
| Molecular Weight | 444.59 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC[C@H](CC(C)C)N(C)S(=O)(=O)C1=CC=C(CN2C(C)=NC3=CN=CC=C23)C=C1
InChI
InChIKey=GFUNPHNHBVCVHW-FQEVSTJZSA-N
InChI=1S/C23H32N4O3S/c1-6-30-16-20(13-17(2)3)26(5)31(28,29)21-9-7-19(8-10-21)15-27-18(4)25-22-14-24-12-11-23(22)27/h7-12,14,17,20H,6,13,15-16H2,1-5H3/t20-/m0/s1
| Molecular Formula | C23H32N4O3S |
| Molecular Weight | 444.59 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Originator
Approval Year
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16921398
Global (whole-heart) delivery of 10 uM nupafant, reduced the incidence of ischaemia-induced VF and widened QT interval without affecting coronary flow. Importantly, lower concentrations (0.1 and 1 uM) had no effect on VF, yet widened QT almost identically to 10 uM nupafant.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:33:40 GMT 2025
by
admin
on
Mon Mar 31 18:33:40 GMT 2025
|
| Record UNII |
02NKI0ARRJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1327
Created by
admin on Mon Mar 31 18:33:40 GMT 2025 , Edited by admin on Mon Mar 31 18:33:40 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9846324
Created by
admin on Mon Mar 31 18:33:40 GMT 2025 , Edited by admin on Mon Mar 31 18:33:40 GMT 2025
|
PRIMARY | |||
|
SUB09391MIG
Created by
admin on Mon Mar 31 18:33:40 GMT 2025 , Edited by admin on Mon Mar 31 18:33:40 GMT 2025
|
PRIMARY | |||
|
7206
Created by
admin on Mon Mar 31 18:33:40 GMT 2025 , Edited by admin on Mon Mar 31 18:33:40 GMT 2025
|
PRIMARY | |||
|
C515030
Created by
admin on Mon Mar 31 18:33:40 GMT 2025 , Edited by admin on Mon Mar 31 18:33:40 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104467
Created by
admin on Mon Mar 31 18:33:40 GMT 2025 , Edited by admin on Mon Mar 31 18:33:40 GMT 2025
|
PRIMARY | |||
|
02NKI0ARRJ
Created by
admin on Mon Mar 31 18:33:40 GMT 2025 , Edited by admin on Mon Mar 31 18:33:40 GMT 2025
|
PRIMARY | |||
|
DTXSID20160933
Created by
admin on Mon Mar 31 18:33:40 GMT 2025 , Edited by admin on Mon Mar 31 18:33:40 GMT 2025
|
PRIMARY | |||
|
C81564
Created by
admin on Mon Mar 31 18:33:40 GMT 2025 , Edited by admin on Mon Mar 31 18:33:40 GMT 2025
|
PRIMARY | |||
|
100000083608
Created by
admin on Mon Mar 31 18:33:40 GMT 2025 , Edited by admin on Mon Mar 31 18:33:40 GMT 2025
|
PRIMARY | |||
|
139133-27-0
Created by
admin on Mon Mar 31 18:33:40 GMT 2025 , Edited by admin on Mon Mar 31 18:33:40 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|